Jonathan D Schoenfeld
Overview
Explore the profile of Jonathan D Schoenfeld including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
131
Citations
2838
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morris Z, Demaria S, Monjazeb A, Formenti S, Weichselbaum R, Welsh J, et al.
Lancet Oncol
. 2025 Mar;
26(3):e152-e170.
PMID: 40049206
Radiotherapy both promotes and antagonises tumour immune recognition. Some clinical studies show improved patient outcomes when immunotherapies are integrated with radiotherapy. Safe, greater than additive, clinical response to the combination...
2.
Moreno A, Watson E, Humbert-Vidan L, Peterson D, van Dijk L, Urbano T, et al.
Int J Radiat Oncol Biol Phys
. 2025 Jan;
PMID: 39826846
Purpose: Osteoradionecrosis of the jaw (ORNJ) is a severe iatrogenic disease characterized by bone death after radiation therapy (RT) to the head and neck. With over 9 published definitions and...
3.
Rettig E, Schoenfeld J, Miller J, Sargent B, Carey E, Margalit D, et al.
Clin Cancer Res
. 2024 Dec;
PMID: 39715483
Background: Observational studies suggest circulating tumor HPV DNA may facilitate early detection of recurrent HPV-positive oropharynx cancer (OPC). We prospectively investigated whether biomarker-guided surveillance detects recurrence sooner than standard-of-care. Patients...
4.
Schoenfeld J, Haas-Kogan D, ONeill A
Lancet
. 2024 Dec;
404(10471):2603-2604.
PMID: 39709209
No abstract available.
5.
Ng W, Huang S, Henson C, Bakst R, Paterson C, Schoenfeld J, et al.
Int J Radiat Oncol Biol Phys
. 2024 Dec;
121(1):1-7.
PMID: 39674598
No abstract available.
6.
Schoenfeld J, Azad N, Gross J, Chen L, Overman M, Kao K, et al.
Clin Cancer Res
. 2024 Dec;
31(4):667-677.
PMID: 39670863
Purpose: Mismatch repair-deficient (dMMR) tumors have demonstrated favorable responses to immune checkpoint inhibition targeting PD-1. However, more in-depth identification of predictors of response could further refine patient selection for immunotherapy...
7.
Zhao M, Schoenfeld J, Egloff A, Hanna G, Haddad R, Adkins D, et al.
Nat Rev Clin Oncol
. 2024 Dec;
22(2):83-94.
PMID: 39658611
Immune-checkpoint inhibitors (ICIs) are being tested as neoadjuvant therapies in various solid tumours, including in patients with head and neck squamous cell carcinoma (HNSCC), with promising results. Key findings thus...
8.
Sun L, Cohen R, DAvella C, Singh A, Schoenfeld J, Hanna G
JAMA Netw Open
. 2024 Aug;
7(8):e2428526.
PMID: 39158913
Importance: Immune checkpoint inhibition (ICI) is a frontline treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), but questions remain surrounding optimal duration of therapy, benefits...
9.
Mouw K, Wisdom A, Schoenfeld J
Int J Radiat Oncol Biol Phys
. 2024 Aug;
120(1):302.
PMID: 39147437
No abstract available.
10.
Liu K, Shin K, Thakuria M, Schoenfeld J, Tishler R, Silk A, et al.
Cancer
. 2024 Aug;
130(24):4267-4275.
PMID: 39101686
Background: Serum antibodies to the Merkel oncoprotein (AMERK) are detectable in approximately 50% of patients with Merkel cell carcinoma (MCC) and can be used to monitor for recurrence. The objective...